Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

A Mixed-Method Study for Implementation of Central Line-Associated Bloodstream Infection Control in Intensive Care Units

10. november 2026 opdateret af: Peking University First Hospital

Implementation of Central Line-Associated Bloodstream Infection Control in Intensive Care Unit Settings: A Mixed-Method Study

This is a phased mixed-method implementation study aiming to develop and evaluate a multi-component central-line-associated bloodstream infection (CLABSI) prevention bundle in three intensive-care units (Respiratory Intensive Care Unit, RICU; Surgical Intensive Care Unit, SICU; Neonatal Intensive Care Unit, NICU) at Peking University First Hospital. This study will first conduct pilot testing of the refined bundle in NICU, then scale-up implementation across all three ICUs. CLABSI incidence rate per 1000 central line-days is the primary outcome; bundle adherence rate and multi-dimensional implementation outcomes are secondary outcomes.

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

1200

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

    • Beijing Municipality
      • Beijing, Beijing Municipality, Kina, 100034
        • Rekruttering
        • Peking University First Hospital
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Liuyi Li, MMSc
        • Ledende efterforsker:
          • Hongling Chu, Ph.D.
        • Ledende efterforsker:
          • Xi Yao, MMSc
        • Underforsker:
          • Meihua Hu, MMSc
        • Underforsker:
          • Yuan Cheng, M.D.
        • Underforsker:
          • Tian Sang, M.D.
        • Underforsker:
          • Cui Yuan, MMSc

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Barn
  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Admitted to RICU, SICU or NICU of Peking University First Hospital during study period
  2. Has an indwelling central venous catheter (CVC, non-tunneled), peripherally inserted central catheter (PICC), or umbilical venous catheter (UVC)
  3. Generates central-line-days within study observation window

Exclusion Criteria:

  1. CVC placed in external hospitals and not managed within the three participating ICUs
  2. Central-line-days generated outside study observation period

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Forebyggelse
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: CLABSI Prevention Bundle Intervention Arm

Single-group intervention, implementing multi-component CLABSI prevention bundle in NICU, RICU and SICU with phased roll-out

A multi-component CLABSI prevention bundle with six core measures: (1) preferable insertion site selection, (2) hand hygiene, (3) maximum sterile barrier precautions, (4) catheter hub disinfection and insertion site care, (5) timely removal of non-essential catheters, and (6) implementation of a standardized checklist. The study adopts a phased implementation design: a pilot phase will first be conducted in NICU to test the bundle, identify implementation barriers, and refine local strategies; after optimization, the refined bundle will be rolled out across RICU, SICU and NICU. Local implementation teams will develop tailored action plans, monitor adherence, and iteratively optimize implementation strategies throughout the study.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
CLABSI incidence rate
Tidsramme: Baseline through intervention period, up to 36 months

CLABSI cases per 1000 central-line-days, defined according to Centers for Disease Control and Prevention (CDC) National Healthcare Safety Network (NHSN) criteria. Calculated as number of CLABSI events divided by total central-line-days multiplied by 1000, collected prospectively in RICU, SICU and NICU.

Baseline through intervention period, up to 36 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Overall CLABSI prevention bundle adherence score
Tidsramme: Baseline through implementation period, up to 36 months

A composite adherence score calculated as the mean proportion of correctly performed elements across six core CLABSI-prevention bundle measures (hand hygiene, maximum sterile barrier precautions, preferable insertion site, disinfection and site care, nonessential catheter removal, and checklist completion), assessed by direct observation and chart review. The score is expressed as a single percentage ranging from 0% to 100%.

Baseline through implementation period, up to 36 months
Acceptability of the CLABSI prevention intervention bundle
Tidsramme: Entire study duration, up to 36 months

Acceptability will be assessed through semi-structured interviews with healthcare professionals involved in implementation to explore perceptions of whether the intervention bundle is agreeable and satisfactory in routine clinical practice. Findings will be reported as qualitative themes and categories.

Entire study duration, up to 36 months
Fidelity of implementation of the intervention bundle - Quantitative assessment
Tidsramme: Entire study duration, up to 36 months

The degree to which the intervention bundle is implemented as intended according to predefined implementation procedures, assessed by quantitative process indicators, case audits, and checklists. Fidelity will be reported as the proportion of predefined procedures correctly completed.

Entire study duration, up to 36 months
Fidelity of implementation of the intervention bundle - Qualitative assessment
Tidsramme: Entire study duration, up to 36 months

The degree to which the intervention bundle is implemented as intended, assessed through semi-structured interviews with implementation stakeholders. Qualitative findings regarding barriers and facilitators to implementation fidelity will be reported as themes.

Entire study duration, up to 36 months
Feasibility of implementation of the intervention bundle
Tidsramme: Entire study duration, up to 36 months

Feasibility will be assessed through semi-structured interviews with healthcare professionals to determine the extent to which the intervention bundle can be successfully implemented within participating intensive care units. Findings will be reported as qualitative themes describing barriers and facilitators to implementation.

Entire study duration, up to 36 months
Sustainability of implementation of the intervention bundle - Quantitative assessment
Tidsramme: Entire study duration, up to 36 months

The extent to which implementation of the intervention bundle is maintained over time, assessed using quantitative process indicators. Sustainability will be reported as the proportion of bundle elements continued in routine clinical practice.

Entire study duration, up to 36 months
Sustainability of implementation of the intervention bundle - Qualitative assessment
Tidsramme: Entire study duration, up to 36 months

The extent to which implementation of the intervention bundle is integrated into routine clinical practice over time, assessed through semi-structured interviews. Qualitative findings will be reported as themes.

Entire study duration, up to 36 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Shuo Li, M.D., Peking University First Hospital

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

1. november 2024

Primær færdiggørelse (Anslået)

1. december 2026

Studieafslutning (Anslået)

1. december 2026

Datoer for studieregistrering

Først indsendt

24. september 2026

Først indsendt, der opfyldte QC-kriterier

10. november 2026

Først opslået (Faktiske)

17. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

17. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

10. november 2026

Sidst verificeret

1. august 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 2024-197-002
  • 23-515 (Andet bevillings-/finansieringsnummer: China Medical Board)
  • 2024研197-002 (Anden identifikator: Peking University First Hospital Ethics Committee)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

IPD-planbeskrivelse

Individual-participant data will not be shared publicly because of patient privacy restrictions and local institutional data security requirements. Aggregated study results may be published in peer-reviewed journals.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner